GlassScriptPhysician profile
Ashley Goble
NPI 1508323163
$6,093.66
in general payments reported to CMS, 2019-2025
22 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $858 · 2022: $599 · 2023: $1,335 · 2024: $1,568 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,538 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,537.52 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,345.27 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $953.51 | 2021-2025 | |
| Ucb, INC. | $877.48 | 2021-2025 | Cimzia, Bimzelx |
| Amgen INC. | $688.16 | 2021-2025 | Tavneos, Enbrel, Otezla |
| Astrazeneca Pharmaceuticals LP | $654.70 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $619.43 | 2021-2025 | Tremfya |
| Pfizer INC. | $255.37 | 2021-2025 | |
| United Therapeutics Corporation | $102.93 | 2023-2024 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $102.59 | 2021-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.78 | 2021-2023 | Cyltezo, Ofev |
| Tonix Medicines, INC. | $62.65 | 2025 | Tonmya |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.06 | 2024-2025 | Caplyta |
| Sobi, INC | $44.31 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $44.26 | 2023-2024 | Acthar |
| Lilly USA, LLC | $41.54 | 2024 | Taltz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $37.84 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $32.76 | 2023 | Trintellix |
| Ultragenyx Pharmaceutical INC. | $24.18 | 2021 | |
| Sandoz INC. | $24.02 | 2023 | Hyrimoz |
| Glaxosmithkline, LLC. | $19.45 | 2021 | |
| Fresenius Kabi USA, LLC | $15.25 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $15.12 | 2023 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Goble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.